An observational study in Sacroiliac Joint Dysfunction and Sacroiliac Joint Pain, sponsored by PainTEQ, LLC. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by PainTEQ, LLC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Arthralgia with a site in United States — 17 open to participants now, 23 under way, 4 of them phase 3. Arthralgia · United States.
Among the 106 studies in Arthralgia with a site in United States, this one is the 12th largest by planned enrollment of the 18 observational ones that give a count, is one of 8 that started in 2026, is one of 18 observational ones, reaches primary completion later than 11 of the 22 other live ones, and was the 101st registered.
277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.
Browse Arthralgia studies →17 of the 106 studies in Arthralgia with a site in United States are open now. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 18+
PainTEQ, LLC · Sites in United States
Ages 21+
Weill Medical College of Cornell University · Sites in United States
Ages 18–75
Veterans Medical Research Foundation · Sites in United States
Ages 18–65
ESM Technologies, LLC · Sites in United States
Ages 18–40 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Arthralgia studies recruiting now, 18 (51%) set no upper age limit and 16 (46%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 20 · Phase 4 6
First in 2004; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 114 across 50 observational studies indexed under Arthralgia.
Median enrollment 82 across the 88 interventional studies, 144 across the 18 observational. Of the 67 that completed or were terminated, 24 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 106 have an industry lead sponsor. The 10 most frequent:
PainTEQ, LLC is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
PainTEQ, LLC has 2 studies filed under Arthralgia — fewer than ten, so there is no comparison to draw.
7 of the studies in Arthralgia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT05621369Sage BionetworksPsorcast Mobile Study | 2027-01-31 |
| NCT04994249Stanford UniversityDiagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation | 2027-04-25 |
| NCT07547215PainTEQ, LLCPost-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies in Arthralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the real-world performance, safety and efficacy of the TRAQ System.
Subjects with chronic, SIJ pain will be screened for participation in this study. Subjects who provide informed consent and meet the study eligibility criteria will be enrolled and will undergo an implant procedure. Subjects will be followed up at 3-, 6-, 12-, 18-, and 24-months following the implant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible to participate in this study, a subject must meet all the following criteria, as determined by the Investigator:
Age and (BMI)
Chronic SIJ Related Pain
Diagnosis of SIJ Dysfunction
a. Has a diagnosis of SIJ dysfunction (degenerative sacroiliitis or SIJ disruption) based on ALL of the following: i. A positive Fortin's finger test; and ii. Pain elicited on at least three (3) of five (5) SIJ specific physical examination maneuvers (FABER test, Gaenslen's test, Distraction, Thigh Thrust, Compression); and iii. At least 75% reduction in pain, with associated improvement in previously painful maneuvers, for the expected duration of action following two (2) image guided, contrast enhanced intra articular diagnostic SIJ injections, performed on separate visits using anesthetics with different durations of action; and iv. Completion of at least one (1) therapeutic intra articular SIJ injection (e.g., injection) within the past 12 months.
Baseline Disability and Pain Severity
a. Baseline Oswestry Disability Index (ODI) score ≥30%; and b. Baseline SI joint pain score of ≥60 mm on a 100 mm Visual Analog Scale (VAS).
and Compliance
Exclusion Criteria:
Subjects must meet none of the following criteria to be eligible for participation in this study, as determined by the Investigator:
Pain Source Uncertainty
a. Inability to confirm, in the Investigator's clinical judgment, that the subject's primary pain generator is the sacroiliac joint.
Alternative Primary Spine Pathology
a. Presence of severe low back pain attributable to other spinal pathology, including but not limited to lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, or lumbar vertebral body fracture.
Non SIJ Pain Syndromes
a. History of coccydynia or prior coccygectomy, endometriosis, cluneal neuralgia, or pudendal neuralgia.
Recent Sacral Interventions
a. Prior sacral radiofrequency ablation performed within 6 months prior to enrollment.
Recent Pelvic Trauma
a. History of major pelvic trauma within 12 months prior to enrollment.
Severe Osteoporosis
a. Prior diagnosis or suspicion of severe osteoporosis, defined as a prior bone mineral density T score of \< -2.5 or a history of osteoporotic fracture.
Medications Affecting Bone or Soft Tissue Healing
a. Current use of medications known to adversely affect bone quality or soft tissue healing, as determined by the Investigator.
Anatomic Constraints
a. Anatomic anomalies or defects that, in the Investigator's opinion, would preclude safe or biomechanically appropriate device placement.
Systemic Inflammatory or Rheumatologic Disease
a. Presence of a chronic inflammatory rheumatologic condition, such as rheumatoid arthritis.
Centralized Pain Syndromes
a. Current diagnosis of fibromyalgia.
Infection Risk
a. Evidence of current local or systemic infection that would increase surgical risk.
High-Dose Opioid Therapy (≥90 MME/day)
a. Current use of systemic opioid analgesics at Screening/Baseline with an average daily dose ≥90 morphine milligram equivalents (MME/day), based on medication reconciliation (prescription records and subject report) and standard MME conversion factors.
Current Nicotine Use (Self-Reported)
a. Self-reported use of any nicotine-containing products (including smoking, vaping/e-cigarettes, cigars, pipes, smokeless tobacco, nicotine pouches, and nicotine replacement products) within 6 weeks prior to Screening/Baseline.
Secondary Gain or Litigation
a. Currently receiving or actively seeking workers' compensation or disability benefits or involved in injury related litigation.
Pregnancy
a. Currently pregnant or planning to become pregnant within two (2) years following enrollment, as self reported.
Vulnerable Populations
a. Individuals who are prisoners or wards of the state.
Substance Abuse
a. Known or suspected active drug or alcohol abuse, including opioid misuse.
Psychiatric Conditions
a. Diagnosed psychiatric disorder (e.g., schizophrenia, major depressive disorder, personality disorder) that, in the Investigator's judgment, could interfere with study participation.
Concurrent Interventional Research
a. Current participation in another clinical trial.
Neurologic Conditions Affecting Rehabilitation
a. Presence of a significant neurologic disorder that would interfere with participation in physical therapy or post procedural rehabilitation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The PainTEQ TRAQ™ Posterior SI Joint Implant is processed human bone tissue that has been precision milled from cortical and cancellous bone. The allograft pierces the SI joint cortices and provides a scaffold around which new bone can grow.
Composite safety and efficacy endpoint
Composite Success Responder Rate at Month 6 Unit of Measure: Percentage of participants Description: The primary endpoint is a single binary (Yes/No) composite responder classification per subject at Month 6. A subject is classified as a composite success responder ONLY if ALL three of the following criteria are met: 1. Pain Improvement: Reduction in SIJ pain VAS score of ≥20 mm from baseline to Month 6 (VAS measured on 0-100 mm scale). 2. Safety: Absence of any device-related or procedure-related SAEs through Month 6 (Day 180). 3. Surgical Reintervention: No surgical reintervention for SIJ fusion through Month 6 (Day 180), including device removal (complete or partial), device revision or replacement, or reoperation at the index SIJ. Subjects meeting all three components are classified as responders; the outcome is reported as the percentage (%) of participants classified as responders.
Time frame: Month 6
Visual Analog Scale (VAS)
Change from baseline in VAS score (measured on 0-100 mm scale) and proportion achieving VAS MCID ≥ 20 mm.
Time frame: Months 3, 6, 12, 18, 24.
Oswestry Disability Index (ODI)
Change from baseline in ODI and proportion achieving ODI MCID ≥ 15 points.
Time frame: Months 3, 6, 12, 18, 24
Patient-Reported Outcomes Measurement Information System (PROMIS-29+2)
Change in T-scores from baseline
Time frame: Months 3, 6, 12, 18, 24
EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire
Change in EQ-5D-5L index scores from baseline
Time frame: Months 3, 6, 12, 18, 24
Patient Global Impression of Change (PGIC)
PGIC categorical distribution
Time frame: Months 3, 6, 12, 18, 24
Medication use
Medication use (including daily MME for opioids) per visit
Time frame: 3, 6, 12, 18, 24
Healthcare Resource Utilization (HCRU)
HCRU per visit
Time frame: Months 3, 6, 12, 18, 24
Plan to share: No — Sponsored Study.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jul 2027, 14 months after the start.
Of 21 observational studies under Arthralgia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 56. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.